Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: Paramyxoviridae Infections, Virus Diseases

In brief

Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease. The purpose of this study is to test the safety of and immune response to a new HPIV vaccine in healthy infants, children, and adults.

Key facts

Study ID

NCT00366782

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

51

Starts

2007-03-01

Expected to finish

2011-06-01

Last updated by the study team

2012-03-01

Who can join

Age: 1 and older, up to 49. Sex: any. Healthy volunteers: accepted.

Where it is running

• Center for Immunization Research — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.